Merck Announces Success of KEYLYNK-001 Trial in Ovarian Cancer Treatment
Merck, known as MSD outside the U.S. and Canada, has achieved a major milestone in cancer research. The pharmaceutical giant announced that its phase 3 KEYLYNK-001 trial has met the primary endpoint of progression-free survival (PFS) for patients with BRCA non-mutated advanced epithelial ovarian cancer. This breakthrough highlights the potential of combining Keytruda (pembrolizumab) and Lynparza (olaparib), with or without bevacizumab, as a first-line treatment.
Key Findings
An independent Data Monitoring Committee concluded that the combination of Keytruda and Lynparza showed a statistically significant and clinically meaningful improvement in PFS compared to chemotherapy alone.
However, the trial did not reach its secondary endpoint of overall survival (OS). The safety profiles of Keytruda and Lynparza remained consistent with earlier studies of the drugs as standalone therapies.
These findings will be presented at an upcoming medical conference and discussed with regulatory bodies.
Addressing Unmet Needs
“For people living with ovarian cancer, there remains an unmet need for new treatment options that have the potential to improve outcomes,” stated Dr. Gursel Aktan, Vice President of Global Clinical Development at Merck Research Laboratories.
This is the first phase 3 trial to demonstrate positive results for Keytruda combined with Lynparza, reflecting Merck’s commitment to advancing care for women’s cancers.
Ovarian Cancer: The Bigger Picture
Ovarian cancer is the seventh most common cancer among women worldwide, with over 324,000 cases diagnosed and more than 206,000 deaths reported in 2022. In the United States alone, approximately 19,680 new cases and 12,740 deaths are projected in 2024.
The standard first-line treatment aims to delay disease progression and achieve long-term remission, but many patients with BRCA non-mutated ovarian cancer face limited options for sustained results.
About KEYLYNK-001
KEYLYNK-001 is a randomized, double-blind phase 3 trial evaluating:
- Keytruda plus chemotherapy followed by Keytruda with Lynparza (with or without bevacizumab).
- Primary endpoints: Progression-free survival in tumors expressing PD-L1 and the intention-to-treat population.
- Secondary endpoints: Overall survival and safety.
The trial enrolled 1,367 patients, divided into multiple treatment arms. The results suggest promising implications for patients with BRCA non-mutated tumors, historically less responsive to certain targeted therapies.
About Keytruda and Lynparza
- Keytruda: An anti-PD-1 therapy that boosts the immune system’s ability to detect and destroy cancer cells.
- Lynparza: A PARP inhibitor targeting cancer cells with DNA repair deficiencies, such as BRCA mutations.
Both therapies are supported by robust clinical trial programs, with Lynparza being developed in collaboration with AstraZeneca.
Future Outlook
Merck remains committed to enhancing outcomes for patients with ovarian, cervical, and endometrial cancers through innovative research and partnerships. With over 20 clinical trials involving 18,000 patients globally, the company is striving to redefine standards of care for women’s cancers.
Conclusion
Merck’s success in the KEYLYNK-001 trial represents a leap forward in the treatment landscape for BRCA non-mutated ovarian cancer. While challenges remain, the findings underline the potential of combining immunotherapy and PARP inhibitors to address unmet needs in oncology.
For more updates on pharmaceutical advancements, stay connected with Pharmacy InfoLine.
About Author
